Transitional Care Management: Connecting to Care

August 8, 2018

Transitional care encompasses a broad range of services and environments designed to promote the safe and timely passage of patients between levels of health care, across care settings, and among various providers. Care settings can include a range of points of care such as hospitals, long-term care facilities, rehab centers, skilled nursing facilities, and home health care. Providers can include a variety of care team members such as physicians, specialists, nurses, care/case managers, pharmacists, visiting nurses, nutritionists, interpreters, and transportation assistance.

Spotlight

Development Center for Biotechnology

The Development Center for Biotechnology (DCB) of Taiwan is a non-profit organization supported by the Department of Industrial Technology, Ministry of Economic Affairs. DCB’s objective is to advance Taiwan's biotech-pharma industry by building infrastructure, developing key technologies, and train talented workforces in coordination with government, industry, and academic institutions. In line with Taiwan's current biotech-pharma development policy, which emphasizes value-addition and knowledge-basis, DCB positions itself as a "Preclinical Value-Adding R&D Center for Biopharmaceuticals"​. This role is to be fulfilled by devoting concerted R&D efforts on protein, small molecule and botanical drug leads in the preclinical stage of development and setting top priorities for attaining Investigational New Drug approvals by domestic and foreign regulatory agencies.

OTHER WHITEPAPERS
news image

Understanding the true cost of transparency reporting

whitePaper | December 14, 2022

When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, it introduced new complexities for these businesses.

Read More
news image

Protein fingerprints pave the way for microarray comparison

whitePaper | June 9, 2022

Anaxomics has developed a novel method of analysis for microarray data based on the generation and subsequent comparison of 2D fingerprints for each sample. Microarray results are incorporated into a protein interaction network and embedded with all sorts of biological and medical data.

Read More
news image

The Ultimate Guide to Digitizing Pharma Manufacturing

whitePaper | September 15, 2022

The sheer size of the pharmaceutical industry makes it important for all stakeholders to stay up to date with pharmaceutical industry trends.

Read More
news image

Medical Afairs Transformation in Specialty Pharma

whitePaper | March 6, 2022

Pharmaceutical companies with a medical mindset and an empowered Medical Afairs function are well equipped to meet the needs and expectations of patients and society. Yet, as capacity to understand and serve those needs accelerates.

Read More
news image

BUILDING A TOMORROW-READY LAB

whitePaper | September 8, 2022

Charles Darwin famously said on survival, "It is not the strongest of the species that survives, nor the most intelligent; it is the one most adaptable to change." Resilience has become an essential message in today's post-covid, next-normal world.

Read More
news image

Paving the way for pharma R&D to use FAIR data

whitePaper | December 16, 2019

The use of FAIR (Findable, Accessible, Interoperable and Reusable) data in drug discovery and development could be transformational. But the pharma industry has been slow to embrace FAIR data — partially because of difficulties in establishing the necessary infrastructure and because of internal culture.

Read More

Spotlight

Development Center for Biotechnology

The Development Center for Biotechnology (DCB) of Taiwan is a non-profit organization supported by the Department of Industrial Technology, Ministry of Economic Affairs. DCB’s objective is to advance Taiwan's biotech-pharma industry by building infrastructure, developing key technologies, and train talented workforces in coordination with government, industry, and academic institutions. In line with Taiwan's current biotech-pharma development policy, which emphasizes value-addition and knowledge-basis, DCB positions itself as a "Preclinical Value-Adding R&D Center for Biopharmaceuticals"​. This role is to be fulfilled by devoting concerted R&D efforts on protein, small molecule and botanical drug leads in the preclinical stage of development and setting top priorities for attaining Investigational New Drug approvals by domestic and foreign regulatory agencies.

Events